Skip to contentI
IDEAYA Biosciences, Inc.
I
IDYAIDEAYA Biosciences, Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$51.82M-$51.82MN/M vs Q3 2023 EPS Diluted-$0.60-$0.60N/M vs Q3 2023 Operating Income-$66,893,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IDEAYA Biosciences, Inc. · CIK 1676725 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$49,691,000N/M ended Sep 30, 2024 · filed Nov 4, 2024 · 35 d after period end